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Abstract
Objective—The relationship among education, psychiatric diagnoses and psychotropic
medication use has been explored in the United States, but little is known about patterns in poorer
countries, despite their high documented burden of mental illness. Educational gradients in
diagnosis and psychotropic use were estimated in the United States and Costa Rica – a middle-
income country with universal health insurance.
Methods—Analyses were conducted using data on older adults (ages 60+) in nationally
representative surveys from each country: the 2005 U.S. Medical Expenditures Panel Survey
(n=4788) and the 2005 Costa Rican Longevity and Healthy Aging Study (n=2827). Logistic
regressions examined the effect of lower educational attainment, income and urban residence on
diagnosis and on psychotropic medication use with and without an associated mental illness
diagnosis.
Results—Rates of self-reported diagnoses were lower in the U.S. (12% U.S.; n=598) than in,
Costa Rica (20%; n=526), but may reflect differences in survey wording. Measures of self-
reported and screened depression decreased with education in both countries. Psychotropic
medication use among those with diagnoses increased with education in Costa Rica only.
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Conclusions—We find similar patterns of educational gradients in diagnosis and screening
between the U.S. and Costa Rica, but different patterns of medication use by education.
Differences in stigma and access to care may play an important role in explaining differences
between the countries, though we did not find evidence that insurance affected educational
gradients in the U.S. These analyses increase the evidence on the role of education in the use of
the health care system.
Introduction
Major depressive disorder is the second leading cause of years lived with disability
worldwide, in both high income and developing countries (1). This ranking remained
constant between 1990 and 2010 despite improvements in psychotropic medicine
availability. Descriptive information on the patterns of diagnosis and treatment of depression
in a variety of contexts will promote a better understanding of these global phenomena. This
study compares patterns of mental health diagnosis and psychotropic drug use between the
U.S. and one middle-income country with near-universal health insurance—Costa Rica. We
examine educational gradients within each country, to better characterize the use of
available mental health treatments.
There has been little systematic documentation of psychotropic medicine use patterns in
developing countries. Much more is known from the U.S., where psychotropic medications
are estimated to be under-used among those with a mental health condition but overused
among those without an appropriate diagnosis (2). The use of psychotropic medications in
general populations continues to grow (3). Appropriate use of psychotropic medications has
been shown to lead to improved symptom profiles, lower levels of disability, and greater
productivity (4–6). While most use of psychotropic medications is for acute or maintenance
therapy, as much as a fifth of these medications may be used by persons with no history of
mental illness (2, 7). This may represent off-label innovations in treatment but most off-label
use has been shown to have a low evidence base, may impart side effect risks, and may
represent a waste of scarce resources (2, 8).
Educational gradients in health and access to care, defined as differences that are positively
or negatively related to education level, have been widely documented for many conditions
in the U.S. (9, 10) Self-reported general health in Costa Rica has been shown to improve
with socioeconomic status, but the opposite is true for all-cause mortality, and there are no
strong gradients in risk factors such as diabetes and high cholesterol (11). A comparison of
cardiovascular risk factor gradients between Costa Rica and the U.S. found that educational
gradients were generally stronger in the U.S., but differences varied by disease (12). One
hypothesized mechanism underlying these gradients is that education may lead to higher
income, improving the ability of people to buffer themselves against health risks and to
purchase medical care and the most effective medications to treat disease. Other theories
suggest the importance of improved cognition, relative social status, time preferences, or
reverse causality in which early life disease lowers educational attainment (13). In the U.S.,
socioeconomic status is strongly and inversely related to mental illness across a number of
studies, regardless of how mental illness is defined or measured (5). However, we have
much less information on treatment patterns across more and less-developed countries, or on
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educational patterns within less-developed countries, and in particular little is known within
the Costa Rican context.
Costa Rica is a country of particular interest because of its historic emphasis on progressive
social and health sector programs, including near-universal health insurance. The country
invested heavily in public health initiatives, has strongly promoted primary care initiatives,
and adopted near-universal government health insurance in the 1970s (14). Costa Rica’s
high overall life expectancy, higher even than the United States, has been linked to its social
investments (15). The government health insurance program covers 90% of the population
for care at public facilities; it pays full costs for most hospitalizations and outpatient care,
though some individuals choose to pay out-of-pocket for private ambulatory care. The
publicly-financed delivery system is organized into three main levels. The first consists of
local outpatient clinics that deliver primary care and a restricted list of free medications,
which includes selected tricyclic antidepressants, benzodiazepines, and first-generation
antipsychotics. The second level consists of regional clinics and hospitals with basic
specialized medicine, and the third level is composed of highly specialized hospitals in the
capital, San Jose. In the higher levels, specialists can prescribe the basic list of medications
plus two SSRI and antipsychotics at no cost to the patient if on-formulary. At private
facilities, patients can pay out-of-pocket for a broader array of psychotropic medications, but
only wealthier individuals can typically afford to do so.
The purpose of our study is to examine patterns of self-report, current screening, and
treatment rates by education and demographics among adults aged 60 and over in Costa
Rica in comparison to the U.S. We focus on the older population due to the availability of
high quality data in Costa Rica, but also because of the strong association between
depression and advanced age (16, 17). We use measures of both self-reported diagnosis as
well as survey-based depression screeners in each population, since neither approach alone
is ideal in identifying persons with current or prior history of mental illness. We examine
whether use of the two largest classes of psychotropic medications, antipsychotics and
antidepressants, vary by education level overall and in subgroups defined by diagnosis or
depression screening. We hypothesize that within each country there will be a greater
burden of mental illness among populations with lower education. We also hypothesize that
we will observe few educational gradients in Costa Rica due to uniform insurance coverage
and a generally strong social safety net. In the U.S., we hypothesize greater disparities by
education in both depression and psychotropic medication use; this is due to both the
substantial proportion of this population without prescription coverage in Medicare prior to
Part D, along with gradients in non-medical social determinants of health that have been
implicated in U.S. gradients in many other non-psychiatric conditions(18).
Methods
We used two large, nationally-representative data sources, from Costa Rica and the U.S: the
Costa Rican Longevity and Healthy Aging Study (CRELES), a nationally representative,
probabilistic sample of non-institutionalized adults aged 60 and over (11), from 2005
(n=2827) and the Medical Expenditure Panel Survey (MEPS), nationally representative of
the U.S. non-institutionalized civilian population, from 2005. We included MEPS
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respondents who were age 60 or greater during 2005 (n=5082), and relied on the first round
of interviews rather than the full panel of data, to increase similarity with CRELES.
Sampling weights are used from both data sources to increase generalizability to each
country’s elderly populations.
Measures
Diagnosis was measured in two ways. First, self-reported diagnosis was measured in
CRELES by responses to the question: “Has a physician ever told you that you have a
nervous or psychiatric problem such as depression?” The MEPS does not contain a similarly
worded question, but rather asks respondents to list medical and mental health conditions
with current symptoms, as the cause of disability days, or associated with health services
used during the reference period; only conditions identified as occurring prior to or during
the first round of interviews in 2005 were retained for this analysis. We refer to both of these
as “self-reported diagnosis” for the sake of brevity, but note the substantial differences in
wording. Second, we use measures of depression screening to identify respondents with
current symptoms of depression. In CRELES, the Geriatric Depression Scale (19) was used
to indicate current symptoms of depression, using thresholds of 6 to indicate potential
depression, and 11 to indicate severe depression. In MEPS, probable depression was defined
as a score of 3 or greater on the PHQ2 (20), which has been validated as a depression
screening tool in the elderly (21). In CRELES, the Geriatric Depression Scale was not
obtained from proxy respondents (25% of the sample), while in the MEPS, the PHQ-2 was
obtained from proxies (13%). In sensitivity analyses, we excluded proxy responses and
found very minor changes in results, so the full sample is retained for the reported analyses.
Depression screeners and self-reported diagnoses have notable differences and thus both are
retained for this analysis. Persons with a prior history of depression or other psychiatric
illnesses but without current depression symptomatology may self-report a diagnosis but not
meet current criteria for depression. Persons with undetected illness or greater stigma may
meet current clinical criteria but not self-report a diagnosis.
Psychotropic medication use was measured by either self-reporting current use or bringing
in prescription medication bottles during the interview, regardless of the level of use or the
use of other treatment modalities. In the MEPS, we include only medications begun prior to
the first round of interviews, again to retain consistency with CRELES. We examined the
use of the two largest classes of psychotropic medications, antidepressants and
antipsychotics. Medication names were coded into drug classes by the survey teams and
didn’t require recognition as psychotropic medications by respondents.
Education level was coded into three categories. In the U.S., individuals were classified as
having low education (25%; n=1566; all ns reported in the text are unweighted; multivariate
analyses use complex sampling weights) if less than high school, medium if a high school
graduate (34%; n=1535), and high education if they reported post-secondary education
(41%; n=1687). In Costa Rica, education was coded as low for persons with two or fewer
years of formal education, medium if the respondent completed primary education, and high
for education beyond primary. Urban status was included because education and access to
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care may vary by urbanicity. It was defined in Costa Rica based on census block and in the
U.S. as residence in a Metropolitan Statistical Area.
Analysis Methods
Logistic regression models were run on measures of self-reported diagnosis, screened
depression, and antidepressant or antipsychotic medication use. Survey-weighted models
examined the association between each of these outcome variables and education,
demographics, and urban location separately by country, overall and stratified by diagnostic
status. Both under-reporting of psychiatric diagnoses and off-label use would contribute to
psychotropic medication use in the undiagnosed population, and thus this measure is not
intended to indicate quality. Persons with low and medium education levels were compared
with those with high education, who served as the referent population. Odds ratios are
reported in tables.
Exploratory Analysis—Because of the heterogeneity of insurance sources in the U.S. and
the potential for racial disparities, we ran additional models including insurance status
(Medicaid, Medicare, and private insurance as well as prescription drug coverage), race, and
Latino ethnicity.
We also undertook exploratory analyses on whether education affected the receipt of any
psychotropic medications listed on Costa Rica’s national formulary that general practitioners
(GP) can prescribe, and then on the receipt of medications that require prescriptions from




18% (n=387) of elderly adults in Costa Rica screened positive for depression and 4% (n=84)
were estimated to have severe depression (Table 1). In the U.S., the rate of probable
depression was just over 10% (n=560). The rate of self-reported psychiatric diagnosis in
Costa Rica was almost 20% (n=526). Just over 12% (n=598) of the U.S. sample reported a
mental health condition in the U.S. Although the self-reported diagnosis includes a broader
set of behavioral health conditions than the screeners available in the data, we found
substantial discordance between screened and self-reported diagnoses. In Costa Rica, 39%
(n=125) of those with current mild depression and 49% (n=37) of those with severe
depression self-reported a mental health diagnosis, while 33% (n=177) of those with
probable depression in the U.S. self-reported a diagnosis. A variety of reasons could explain
these differences, including stigma, lack of access to care, and false positives in the
screeners.
Almost 7% (n=179) of the elderly Costa Rican population and almost 8% (n=378) in the
U.S. reported using an antidepressant during the study year. Only 23% (n=110) of elderly
Costa Ricans but 41% (n=249) of Americans with a self-reported diagnosis reported using
antidepressants. Among those without a self-reported diagnosis, the rate of antidepressant
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use among elderly Americans was 3.2% (n=129) and 2.7% (n=69) in Costa Rica.
Antipsychotics had a greater use rate in Costa Rica (2%; n=66) than in the U.S. (.7%; n=31).
Multivariate Analyses: Diagnosis
We found no evidence of educational gradients in self-reported diagnosis in either country,
but do find an educational gradient in screened depression (Table 2). In Costa Rica, the odds
of screening positive for depression among persons with lower education were almost
double those with higher education (OR 1.96; p<.01). In the U.S., we see an even stronger
educational gradient: those with less than high school education had more than three times
the odds of probable depression than those with higher education (OR 3.43, p<.01), and
those with only high school education having almost twice the odds of probable depression
(OR 1.88; p<.01). In the U.S., the odds of self-reporting depression among those with
probable depression and low education were less than half the odds of self-reporting among
those with higher levels of education (OR=.36; p<.01).
Multivariate Analyses: Psychotropic Medication Use
Among the full elderly population, we did not find strong evidence of an educational
gradient in antidepressant use in either country (Table 3). Odds of antidepressant use were
similar in the U.S. population across education categories; differences in the odds of
antidepressant use were lower in less educated Costa Ricans, but these differences were not
statistically significant. However, educational gradients began to emerge in Costa Rica only
as we conducted separate analyses by persons with and without a self-reported history of
psychiatric illness. Among persons with a self-reported diagnosis, the odds of using
antidepressants for the less educated in Costa Rica were only 34% of the odds of use among
the highest educated (p<.01), and the odds among those in the middle level of education
were half (OR .57, p<.05) of the more educated. Among those without a self-reported
diagnosis, the odds of antidepressant use among those with lower education in Costa Rica
was more than 50% greater than those with higher education, but not statistically significant.
Among those without a self-reported diagnosis in the U.S., we saw lower odds of using
antidepressants among those with lower education, but again, the difference was not
statistically significant.
We found evidence of a positive gradient in antipsychotic medication use in Costa Rica,
with persons with lower levels of education having a substantially lower odds of using these
medications than the more educated, although the difference is only statistically significant
for the comparison between medium and high education (OR .31, p<.01). The educational
gradient in the U.S. is negative, but not significant (low education OR 1.9, p>.05). Among
those reporting a history of psychiatric diagnosis, the positive gradient in Costa Rica was
even steeper than in the general population, while the positive gradient in the U.S. was
similar to the general population and again not significant. Among those without a self-
reported condition, we again see a positive educational gradient in Costa Rica, but a
negative gradient in the U.S., although these results are not statistically significant.
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Including insurance, race, and ethnicity in the U.S. models did not affect the results on
educational gradients, but were each generally associated with diagnosis and medication use.
In the exploratory analysis of access to psychotropic medications through the general and
specialty sectors in Costa Rica, we found little evidence of an educational gradient in the
receipt of any psychotropic medications from the GP national formulary, but saw a
significant positive gradient in the receipt of specialty medications (Table 5). Among those
with self-reported diagnoses, however, a large positive gradient in access to psychotropic
medications on the GP formulary appeared, with the lower educated having less than half
the odds (OR=.45; p<.05) of receiving a psychotropic medication covered by the country’s
GP formulary than those with high education; the gradient in specialty prescriptions became
much steeper as well. Finally, among those without self-reported diagnoses, we did not find
strong evidence of educational gradients, although the results are suggestive of greater
access to medications on the GP formulary by the lower educated, and lower access to
restricted medications.
Discussion
The greater prevalence of depression among the less educated in both Costa Rica and the
U.S. is consistent with other studies (e.g., 522). Among those with probable (screened)
depression in the U.S., the lower level of self-reporting among the less educated is consistent
with other literature (18).
Overall, we did not find strong evidence of educational gradients in antidepressant use in
either country. In subsample analyses, however, we found evidence that greater education is
associated with greater treated prevalence among those with diagnoses in Costa Rica,
whereas in the U.S., we saw no such trends by education.
In the U.S., broad Medicaid coverage for persons with low SES may effectively
counterbalance greater access by persons with higher education, thus resulting in fairly equal
access across education groups. In Costa Rica, because of the presence of a national
formulary, use of psychotropics may reflect better access to public specialty care providers
or to private providers by persons with higher education. Further research should explore
whether persons with higher education experience lower stigma or have better knowledge
about mental health care treatment.
We also saw very different patterns for antipsychotic users. In Costa Rica, elderly persons
with greater education had substantially greater use of antipsychotics overall, and in both
diagnosed and undiagnosed samples. In the U.S., the trend was exactly the opposite, with
higher educated respondents less likely to use antipsychotic medications, and a much weaker
association between education and use. The cause of this difference in Costa Rica may be
due to the limitations on prescribing antipsychotic medications in primary care. Although
the national formulary in Costa Rica should preserve access to psychotropic medications for
persons at all education levels, because of the limited number of psychotropic medications
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available through generalists, we found evidence that the lower educated experienced access
barriers to treatment.
These results should be interpreted in light of a number of limitations. Self-reported
psychiatric diagnoses were elicited differently in the two surveys, and the reliance on the
reporting of specific conditions in the MEPS data may create a diagnosed sample that has
experienced symptoms more recently. However, institutionalization rates are lower in Costa
Rica than the US, thus potentially yielding a more acutely ill sample in Costa Rica.
Appropriateness of medication use cannot be determined in these data. Finally, the
concordance between depression diagnosis and antidepressant use may be stronger than the
link between psychiatric diagnosis and antipsychotic medication use, since appropriate
screeners for other psychiatric disorders were not available in either data source.
More fundamentally, better understanding is needed of the underlying cultural factors that
may mediate and moderate education effects in different settings. A review of psychotropic
adherence in the United States documented extensive evidence of substantially lower
adherence among Latinos compared to Euro-Americans (23), but the reasons for this are still
poorly understood. We are not aware of any specific research to date on cultural factors that
vary across education groups in Costa Rica and that could influence psychotropic
medication patterns. Better understanding of such sociocultural factors will be important for
informing culturally-appropriate clinical interventions to address any inappropriate care that
may be substantiated by future work.
Conclusions
We find similar patterns of educational gradients in diagnosis and screening between the
U.S. and Costa Rica, but very different patterns of medication use by education in these two
countries. Differences in stigma and access to care may play an important role in explaining
differences between the countries, though we did not find evidence that insurance affected
educational gradients in the U.S. These analyses increase the evidence on the role of
education in the use of the health care system and health status. Future research should
examine the appropriateness of medication use by education and the influence of greater
health insurance coverage to the elderly and near-elderly in the U.S. from Medicare Part D
and the Affordable Care Act.
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